Pfizer Beats Expectations in Q3 and Raises Its Guidance. Is the Stock Due for a Big Rally?

Pfizer reported strong Q3 results, beating analyst expectations with $16.6B in revenue (vs. $15.9B forecast) and $0.87 EPS (vs. $0.73 expected). The company raised full-year guidance and highlighted 32% growth from launched and acquired products. Trading at a modest 10x forward P/E with a 5.6% dividend yield, the stock may be positioned for further gains despite being down 30% over five years due to declining COVID-related revenues.